Reflecting On Immuno-Oncology Stocks’ Q2 Earnings: Natera (NASDAQ:NTRA) As the Q2 earnings season wraps, let’s dig into this quarter’s best and worst performers in the immuno-oncology industry, including Natera (
NASDAQ:NTRA ) and its peers.
The FDA Just Granted Its Speediest Review Ever. Disc Medicine, Others Fly. The Commissioner's National Priority Review vouchers aims to speed up the review process to just one to two months.
FDA Unveils First Experimental Drugs Under Fast-Track Voucher Plan To Cut Drug Review Times The FDA launched a new voucher program to fast-track reviews, naming nine experimental drugs for cancer, diabetes, addiction, and other conditions.
Regeneron Pharmaceuticals (NASDAQ:REGN) Presents a Compelling Case for Value Investors Regeneron (REGN) presents a strong value investment case with a low P/E ratio, robust financial health, high profitability, and steady growth.
EyePoint Pharmaceuticals Raises Capital As It Advances Lead Product To Pivotal Study EyePoint Pharmaceuticals outlines Phase 3 trials for Duravyu in diabetic macular edema, backed by $150 million in new funding.
2 Stocks Down 17% and 21% to Buy Right Now Both companies have faced recent challenges, but look likely to overcome them.
Why Are Regeneron And Scholar Rock Shares Falling On Monday? Regeneron and Scholar Rock’s submissions have been delayed or denied following an FDA inspection at the third-party fill-finish facility Catalent Indiana, owned by Novo Nordisk.
Regeneron's Gene Therapy Shows Significant Gains In Genetic Hearing Loss Regeneron gene therapy for OTOF-related hearing loss shows rapid, sustained improvements, including normal hearing in some participants.
Investors Brace for Pullback as Short-Bias ETF Inflows Signal Growing Bearishness A significant surge in capital flowing into short-bias Exchange-Traded Funds (ETFs) has sent a clear signal through the financial markets: investor sentiment is shifting towards caution and a potential stock market pullback. This notable trend, particularly pronounced in recent weeks, suggests that a growing number of investors are actively positioning
Regeneron's Libtayo Gains FDA Approval To Reduce Recurrence Risk In Skin Cancer Patients FDA approves Regeneron's Libtayo for adults with high-risk cutaneous squamous cell carcinoma after surgery and radiation, based on Phase 3 trial data.
Why Apogee, A Rival To Regeneron And Sanofi, Rocketed 34% And Broke Out The small biotech company is looking to take on Regeneron and Sanofi's blockbuster, Dupixent.
Retail Buzz Builds Around Regeneron After FDA Clears Libtayo For High-Risk Skin Cancer; Traders Eye ‘Buying Opportunity’ The FDA’s approval of Libtayo was based on Phase 3 trial data showing a 68% reduction in the risk of recurrence or death in high-risk CSCC patients.
Here's Why Nektar Therapeutics Stock Rocketed 90.6% Higher in September Results of the Resolve-AD trial with rezpegaldesleukin were better than expected.
Wednesday's session: top gainers and losers in the S&P500 index Wondering what's happening in today's session for the S&P500 index? Stay informed with the top movers within the S&P500 index on Wednesday.
Health Care Stocks Rally, Nike Beats The Street: What's Moving Markets Wednesday? Wall Street posts modest gains as shutdown begins and jobs data disappoints, but optimism around earnings and rate cuts keeps markets afloat.
Which S&P500 stocks are moving on Wednesday? Let's delve into the developments on the US markets in the middle of the day on Wednesday. Below, you'll find the top gainers and losers within the S&P500 index during today's session.
Nvidia, Amphenol, Lockheed Martin And A Health Care Stock On CNBC's 'Final Trades' Nvidia surges past 52-week high, surpasses $4.5 trillion market cap as tech companies invest in AI. Regeneron and Amphenol named as top trades.
2 Beaten-Down Stocks to Buy and Hold for a Decade These biotechs should benefit from their innovative ways.
